Cardiovascular Systems Stock Forecast, Price & News

Cardiovascular Systems (NASDAQ:CSII) Frequently Asked Questions

Is Cardiovascular Systems a buy right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Cardiovascular Systems in the last twelve months. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Cardiovascular Systems stock.
View analyst ratings for Cardiovascular Systems or view top-rated stocks.

What stocks does MarketBeat like better than Cardiovascular Systems?

Wall Street analysts have given Cardiovascular Systems a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Cardiovascular Systems wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Cardiovascular Systems' next earnings date?

Cardiovascular Systems is scheduled to release its next quarterly earnings announcement on Wednesday, November 3rd 2021.
View our earnings forecast for Cardiovascular Systems.

How were Cardiovascular Systems' earnings last quarter?

Cardiovascular Systems, Inc. (NASDAQ:CSII) posted its quarterly earnings results on Wednesday, August, 4th. The medical device company reported ($0.14) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.17) by $0.03. The medical device company had revenue of $70.99 million for the quarter, compared to analysts' expectations of $69 million. Cardiovascular Systems had a negative net margin of 5.18% and a negative trailing twelve-month return on equity of 4.95%. The company's quarterly revenue was up 66.8% on a year-over-year basis.
View Cardiovascular Systems' earnings history.

How has Cardiovascular Systems' stock been impacted by COVID-19 (Coronavirus)?

Cardiovascular Systems' stock was trading at $36.32 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, CSII shares have decreased by 8.4% and is now trading at $33.27.
View which stocks have been most impacted by COVID-19.

What guidance has Cardiovascular Systems issued on next quarter's earnings?

Cardiovascular Systems updated its FY 2022 earnings guidance on Wednesday, August, 25th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $295 million-$305 million, compared to the consensus revenue estimate of $299.45 million.

What price target have analysts set for CSII?

6 equities research analysts have issued 12 month target prices for Cardiovascular Systems' shares. Their forecasts range from $38.75 to $49.00. On average, they expect Cardiovascular Systems' share price to reach $44.75 in the next year. This suggests a possible upside of 34.5% from the stock's current price.
View analysts' price targets for Cardiovascular Systems or view top-rated stocks among Wall Street analysts.

Who are Cardiovascular Systems' key executives?

Cardiovascular Systems' management team includes the following people:

• Scott R. Ward, Chairman, President & Chief Executive Officer
• Rhonda J. Robb, Chief Operating Officer
• Jeffrey S. Points, Chief Financial Officer
• Ryan D. Egeland, Chief Medical Officer
• Sandra M. Sedo, Chief Compliance Officer

What is Scott Ward's approval rating as Cardiovascular Systems' CEO?

12 employees have rated Cardiovascular Systems CEO Scott Ward on Glassdoor.com. Scott Ward has an approval rating of 81% among Cardiovascular Systems' employees.

Who are some of Cardiovascular Systems' key competitors?

Some companies that are related to Cardiovascular Systems include Abbott Laboratories (ABT), Medtronic (MDT), Intuitive Surgical (ISRG), Stryker (SYK), Becton, Dickinson and (BDX), Edwards Lifesciences (EW), Boston Scientific (BSX), IDEXX Laboratories (IDXX), DexCom (DXCM), Baxter International (BAX), ResMed (RMD), STERIS (STE), Insulet (PODD), Hologic (HOLX) and Teleflex (TFX).
View all of CSII's competitors.

What other stocks do shareholders of Cardiovascular Systems own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cardiovascular Systems investors own include Gilead Sciences (GILD), AbbVie (ABBV), Advanced Micro Devices (AMD), Medtronic (MDT), Pfizer (PFE), (XEL), ACADIA Pharmaceuticals (ACAD), Johnson & Johnson (JNJ), Merck & Co., Inc. (MRK) and The Procter & Gamble (PG).

What is Cardiovascular Systems' stock symbol?

Cardiovascular Systems trades on the NASDAQ under the ticker symbol "CSII."

Who are Cardiovascular Systems' major shareholders?

Cardiovascular Systems' stock is owned by a number of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (17.42%), Brown Capital Management LLC (14.96%), Champlain Investment Partners LLC (8.55%), Vanguard Group Inc. (6.62%), RGM Capital LLC (4.86%) and State Street Corp (3.77%). Company insiders that own Cardiovascular Systems stock include Alexander Rosenstein, Erik Paulsen, Martha Goldberg Aronson, Rhonda J Robb, Sandra Sedo and Scott R Ward.
View institutional ownership trends for Cardiovascular Systems.

Which institutional investors are selling Cardiovascular Systems stock?

CSII stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Renaissance Technologies LLC, Invesco Ltd., Rice Hall James & Associates LLC, Morgan Stanley, Morgan Stanley, Susquehanna International Group LLP, and Bank of New York Mellon Corp.
View insider buying and selling activity for Cardiovascular Systems or view top insider-selling stocks.

Which institutional investors are buying Cardiovascular Systems stock?

CSII stock was purchased by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., RGM Capital LLC, Dimensional Fund Advisors LP, Grandeur Peak Global Advisors LLC, State Street Corp, Millennium Management LLC, Bridgewater Associates LP, and M&G Investment Management Ltd.. Company insiders that have bought Cardiovascular Systems stock in the last two years include Erik Paulsen, Martha Goldberg Aronson, Rhonda J Robb, and Scott R Ward.
View insider buying and selling activity for Cardiovascular Systems or or view top insider-buying stocks.

How do I buy shares of Cardiovascular Systems?

Shares of CSII can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Cardiovascular Systems' stock price today?

One share of CSII stock can currently be purchased for approximately $33.27.

How much money does Cardiovascular Systems make?

Cardiovascular Systems has a market capitalization of $1.34 billion and generates $258.97 million in revenue each year. The medical device company earns $-13,420,000.00 in net income (profit) each year or ($0.35) on an earnings per share basis.

How many employees does Cardiovascular Systems have?

Cardiovascular Systems employs 779 workers across the globe.

When was Cardiovascular Systems founded?

Cardiovascular Systems was founded in 1989.

What is Cardiovascular Systems' official website?

The official website for Cardiovascular Systems is www.csi360.com.

Where are Cardiovascular Systems' headquarters?

Cardiovascular Systems is headquartered at 1225 OLD HWY 8 NW, ST. PAUL MN, 55112.

How can I contact Cardiovascular Systems?

Cardiovascular Systems' mailing address is 1225 OLD HWY 8 NW, ST. PAUL MN, 55112. The medical device company can be reached via phone at (651) 259-1600 or via email at [email protected].